Email this page to a friend

SITE REGISTRATION
Registration benefits include:
  • Access to CME/CE programs and certification
  • Additional information from the provider
  • Reminders of new CME/CE activities and related content
This Web site has been provided through educational grants from:
Genentech, Inc.
Biogen Idec
Amgen
Wyeth
UCB
Now at RAoutlook.org! Doctor-to-Doctor - Click Here
Search Results

9 question(s) listed


Clinical Trials

Management of extra-articular manifestations associated with rheumatoid arthritis
How should I be managing the extra-articular manifestations of RA, such as interstitial lung disease, vasculitis, and scleritis?
  Click here to read answer

Management of common comorbidities associated with rheumatoid arthritis
How do you manage comorbidities such as cardiovascular disease and osteoporosis? Do you team with other specialists, and if so, how?
  Click here to read answer

Mechanism of Action

Rituximab treatment results in the death of specific B-cell populations
What happens to the B cells after a patient receives a course of rituximab infusions?
  Click here to read answer

Side Effects

The influence of rituximab-induced B-cell depletion on infection incidence
Are there known risks associated with the immunologic changes induced by rituximab infusions?
  Click here to read answer

Treatment Considerations

Differences in clinical and radiographic responses between methotrexate and anti-TNF agents
Why is it that the clinical and radiographic responses with methotrexate do not always correlate with one another, but when using anti-TNF agents they do?
  Click here to read answer

Defining inadequate response.
How should I define inadequate response?
  Click here to read answer

Biologic agents in combination with leflunomide and prednisone in a patient with a prior malignancy

What biologic agent, if any, would you use in a patient with severely deforming, very active rheumatoid arthritis who is currently on leflunomide and prednisone? I have a male patient of this description who also has a history of bilateral partial nephrectomy for renal cell carcinoma 2 years ago. Renal function is normal, and there is no evidence of active malignancy at present. He did not respond to methotrexate. Thank you for your reply.
  Click here to read answer

MRI prescreening before the use of rituximab

With recent reports of progressive multifocal leukoencephalopathy (PML) developing in patients treated with rituximab (thus far confined to patients with systemic lupus erythematosus), would it be prudent to prescreen all patients with brain magnetic resonance imaging (MRI) prior to anticipated treatment?
  Click here to read answer

  Doctor to Doctor Home